Source: Annual Congress 2012 - Late breaking results: Asthma from phenotyping to emerging new treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Pavord, S. Korn, P. Howarth, E. Bleecker, R. Buhl, O. Keene, H. Ortega, P. Chanez (Leicester, , Stockley Park, United Kingdom; Mainz, Germany; Winston-Salem, Research Triangle Park, United States Of America; Marseille, France). LATE-BREAKING ABSTRACT: Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. Eur Respir J 2012; 40: Suppl. 56, 349

Member's Comments

No comment yet.

Related content which might interest you: Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo Source: International Congress 2017 – Asthma management Year: 2017 LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 LATE-BREAKING ABSTRACT: Biomarkres in exacerbations of chronic obstructive pulmonary disease (ECOPD) Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 LATE-BREAKING ABSTRACT: Predictive factors of frequent exacerbations in mild grade COPD patients Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care Year: 2016 LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019